Iterum Therapeutics plc

About Iterum Therapeutics plc

Iterum Therapeutics plc is a pharmaceutical company focused on developing and commercializing innovative anti-infective therapies, notably ORLYNVAH®, the first FDA-approved oral penem antibiotic for uncomplicated urinary tract infections in women. Its core business involves advancing sulopenem, a potent antibiotic targeting resistant gram-negative bacteria, through clinical development, regulatory approval, and potential commercialization in the U.S. and globally, addressing critical needs in resistant infections and antimicrobial resistance.